JAZZ

#708
Jazz Pharmaceuticals, Inc.
190.0200
-0.12%
版块:
基础:
利润货币:
日范围
190.0200
190.0200
年范围
128.8000
197.6000
日变化
-0.12%
每月变动
+13.55%
6个月变化
+35.73%
年变化
+35.73%
前一天收盘价
190.2500
Open
190.0200
Bid
Ask
Low
190.0200
High
190.0200
交易量
98
Open full chart

Financials

Overview 声明 Statistics Dividends
Quarterly Annual
Value 202020212022202320242025 TTM
Key stats
Valuation ratios
Profitability ratios
Liquidity ratios
Solvency ratios
Per share metrics

Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland. One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals. In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use. The company is also a member of the Pharmaceutical Research and Manufacturers of America.

新闻